Feb 20, 2020 - Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Feb 11, 2020 - Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Feb 11, 2020 - J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
Feb 10, 2020 - Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.
Feb 07, 2020 - Top Stock Research Reports for Alphabet, Roche & Amgen
Feb 07, 2020 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Feb 06, 2020 - Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Feb 06, 2020 - Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Feb 05, 2020 - Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.